-
@BioXcel_Tx Announces 1st Patient Enrollment in Phase 1b/2 study of#BXCL501 for Acute Treatment of Agitation Associated with Dementia. https://ir.bioxceltherapeutics.com/press-releases/detail/108/bioxcel-therapeutics-announces-first-patient-enrolled-in … -
BioXcel Therapeutics Announces
@US_FDA Clearance of IND Application for#BXCL501 for the Treatment of#Opioid Withdrawal Symptoms.#agitationhttps://ir.bioxceltherapeutics.com/press-releases/detail/109/bioxcel-therapeutics-announces-fda-clearance-of-ind … -
#BTAI Prepares to Initiate Pivotal Phase 3 with#BXCL501 Following Positive End-of-Phase 2 Meeting with@US_FDAhttps://ir.bioxceltherapeutics.com/press-releases/detail/105/bioxcel-therapeutics-prepares-to-initiate-pivotal-phase-3 … -
The
@US_FDA has granted Fast Track designation to#BXCL501, an investigational treatment for#acuteagitation.http://ow.ly/Llta30ndVmW -
#BTAI supports@WMHDay & challenges people face with#mentalhealth.#BXCL501 Phase 3 results expected 1H 2020 for those suffering from#schizophrenia#bipolardisorder.#WorldMentalHeathDaypic.twitter.com/Dfmm4HORy4 -
#BioXcelTherapeutics Wins#Award by#US. Department of Defense#Congressionally Directed Medical#Research Programs (#CDMRP) for#BXCL501 Development. https://www.trialsitenews.com/bioxcel-therapeutics-achieved-wins-award-by-u-s-department-of-defense-congressionally-directed-medical-research-programs-cdmrp-for-bxcl501-development/ … via@Trial Site News @BioXcelTherapeutics#departmentofdefense#medicalresearchprograms#clinicaltrials -
BioXcel Therapeutics
$BTAI to Ring the@NASDAQ Stock Market Opening Bell on April 20, 2018. Join us live: https://livestream.com/nasdaq/live#RewriteTomorrow#OpeningBell#ImmunoOncology#BXCL701#Neuroscience#BXCL501#AIpic.twitter.com/cKa18Pmbtv
-
Thank you
@AllieRN13 and@PharmaTechFocus for the in-depth article in@medicaltechmag- Triple Combo: Calming#Alzheimer's Agitation With#AI,#Wearables And A Novel Drug- highlighting@BioXcel_Tx and its phase 3 therapy.#BXCL501 https://medical-technology.nridigital.com/medical_technology_jan20/triple_combo_calming_alzheimer_s_agitation_with_ai_wearables_and_a_novel_drug … -
Thanks,
@YahooFinance for the mention! "Get in On the#AI Health Care Revolution with@GlobusMedical@apple@amazon@Google"#BTAI#BXCL501#BXCL701https://finance.yahoo.com/news/ai-health-care-revolution-globus-231333236.html … -
Our CEO and founder Dr. Vimal Mehta shared
#BXCL501's exciting news with@proactive_NA.#BTAI is developing#wearable (such as@apple watch) to help combat#agitation.#applewatch#bif2019pic.twitter.com/KaNFMsMsVi
-
#BTAI highlights major milestones.#BXCL501 data expected 1H 2020.#BXCL701 data expected Q4 2019 & 1H 2020.https://ir.bioxceltherapeutics.com/press-releases/detail/100/bioxcel-therapeutics-highlights-upcoming-major-milestones … -
#BioXcel#Therapeutics hopes to use wearable digital devices like the@Apple#Watch to predict whether patients with#Alzheimer’s are becoming agitated, so that the company’s drug#BXCL501 can be administered to prevent the episode from escalating. https://bit.ly/32XlgeR
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.